

Europad

European Opioid Addiction Treatment Association

Per aspera ad astra

Affiliated to INTERNATIONAL SOCIETY OF ADDICTION MEDICINE



Since 1994

AU-CNS

Association for the Application
of Neuroscientific Knowledge
to Social Aims




World Federation for the
Treatment of
Opioid Dependence

NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)

16th European Congress

Heroin Addiction & Related Clinical Problems

European Opioid Addiction Treatment Association - EUROPAD



June 28-30, 2024

www.europad.org; www.europadevents.org; www.heroinaddictionrelatedclinicalproblems.org



PISA

School of Addiction Medicine

SANA Malhoa Hotel
Lisbon, Portugal, EU

PROGRAMME



Addiction Research Methods Institute

World Federation for the Treatment of Opioid Dependence

Pisa, Italy, EU - New York, NY, USA

30th year

President

Icro Maremmani
Pisa, Italy, EU

Vice-President

Marc Reisinger
Brussels, Belgium, EU

General Secretary

Andrej Kastelic
Ljubljana, Slovenia, EU

Chairs National Scientific Committees


Albania	Genci Mucullari <i>Tirane, Albania</i>	Kosovo	Safet Blakaj Milazim Gjocjaj <i>Pristina, Kosovo</i>
Australia	Nicholas Lintzeris <i>Sydney, NSW, Australia</i> Adrian Dunlop <i>Newcastle, Australia</i>	Lithuania	Emilis Subata <i>Vilnius, Lithuania, EU</i>
Austria	Gabriele Fischer Arkadiusz Komorowski <i>Vienna, Austria</i>	Netherlands	Peter Vossenbergh <i>Deventer, Netherlands</i>
Belarus	Oleg Aizberg Sergey Igumnov <i>Minsk, Belarus</i>	North Macedonia	Liljana Ignjatova Aneta Spasovska Trajanovska <i>Skopje, North Macedonia</i>
Belgium	Marc Reisinger <i>Brussels, Belgium, EU</i>	Norway	Thomas Clausen <i>Oslo, Norway</i>
Bosnia and Herzegovina	Nermana Mehic-Basara <i>Sarajevo, Bosnia & Herzegovina</i>	Poland	Edward Jacek Gorzelanczyk <i>Bydgoszcz, Poland, EU</i>
Bulgaria	Alexander Kantchev <i>Sofia, Bulgaria, EU</i>	Portugal	Celia Maria Franco <i>Coimbra, Portugal, EU</i> Luis Patricio <i>Lisbon, Portugal, EU</i>
Croatia	Ante Ivancic <i>Porec, Croatia, EU</i>	Romania	Adrian Octavian Abagiu <i>Bucarest, Romania</i>
Finland	Hannu Alho <i>Helsinki, Finland</i>	Russia	Vladimir Mendelevich <i>Kazan, Russia</i>
France	Marc Auriacombe <i>Bordeaux, France</i> Maurice Dematteis <i>Grenoble, France</i>	Scotland, UK	Duncan Hill <i>Lanarkshire, Scotland, UK</i>
Germany	Albrecht Ulmer <i>Stuttgart, Germany, EU</i> Stephan Walcher <i>Munich, Germany, EU</i>	Serbia	Minja Jovanovic <i>Kragujevac, Serbia</i>
India	Yatan Pal Singh Balhara Siddharth Sarkar <i>New Delhi, India</i>	Slovakia	Okruhlica Lubomir <i>Bratislava, Slovakia, EU</i>
Ireland	Garrett McGovern <i>Dublin, Ireland, EU</i>	Slovenia	Andrej Kastelic Mercedes Lovrecic <i>Ljubljana, Slovenia, EU</i>
Israel	Einat Peles <i>Tel Aviv, Israel</i>	Spain	Francina Fonseca Marta Torrens <i>Barcelona, Spain, EU</i>
Italy	Matteo Pacini <i>Pisa, Italy, EU</i> Lorenzo Somaini <i>Biella, Italy, EU</i>	Sweden	Leif Gronbladh <i>Uppsala, Sweden</i>
		Switzerland	Thierry Favrod-Coune Daniele Zullino <i>Geneve, Switzerland</i>
		Ukraine	Sergey Dvoriak <i>Kiev, Ukraine</i>

Under the Patronage of

World Federation for the Treatment of Opioid Dependence, New York, NY, USA
NGO with Special Consultative Status with United Nations Economic and Social Council (ECOSOC)
New York, NY, USA

World Federation for the Treatment of Opioid Dependence Executive Committee

President



Icro Maremmani
(Italy)

Vice President



Mark W. Parrino
(USA)

Treasurer



Michael Rizzi
(USA)

Corporate Secretary



Marc Reisinger
(Belgium)

Promoted by

European Opioid Addiction Treatment Association,
Brussels, Belgium - Pisa, Italy, EU

Executive Committee

President



Icro Maremmani
(Italy)

Vice President




Marc Reisinger
(Belgium)

General Secretary



Andrej Kastelic
(Slovenia)

Association for the Application of Neuroscientific Knowledge to Social Aims,
Pietrasanta, Italy, EU



Pisa School of Addiction Medicine,
Pisa, Italy, EU



Icro Maremmani
Mario Miccoli

Silvia Bacciardi
Manuel Glauco Carbone
Filippo Della Rocca
Francesco Lamanna
Marco Maiello
Angelo G. I. Maremmani
Matteo Pacini
Alessandro Pallucchini
Vincenza Spera
Claudia Tagliarini

Marilena Guareschi

Pier Paolo Pani
Lorenzo Somaini
Sarah Vecchio

MAIN PRESENTATIONS



MARC AURIACOMBE
(Bordeaux, France, EU)
**Why Is Craving So Important?
What to Do About It?**



ANGELO G. I. MAREMMANI
(Pisa, Italy, EU)
**Chronic Psychoses and Opioid
Medications**



MAURICE DEMATTEIS
(Grenoble, France, EU)
**Treating Pain in Opioid Use
Disorders**



MARC PARRINO
(New York, NY, USA)
**Overdoses with Opioid Treatment/
Long-Acting Politics**



GABRIELE FISCHER
(Vienna, Austria, EU)
**Medical Standards and Human
Rights for Diagnosis and Treatment
of Opioid Dependence in Prison**



EINAT PELES
(Tel Aviv, Israel)
**Nutrition, Eating Habits and Weight
Reduction Intervention among Opioid
Maintenance Treatment Patients**



ANDREJ KASTELIC
(Ljubljana, Slovenia, EU)
**Experience with Buprenorphine
s.c. Depot Injection and Induction
with Microdosing in Slovenia**



REISINGER MARC
(Brussels, Belgium, EU)
**Is it Possible to Detoxify Patients
with a Long-Acting Opioid
Medication?**



MICHAEL KRAUSZ
(Vancouver, BC, Canada)
**Opioid Overdose Crisis in
Northern America and Its Potential
Impact on Europe**



LORENZO SOMAINI
(Biella, Italy, EU)
**What is Changing with Opioid Long-
Acting Medications?**



NICHOLAS LINTZERIS
(Sydney, NSW, Australia)
**Patient-Reported Outcomes of
Treatment of Opioid Dependence
With Weekly and Monthly
Subcutaneous Depot**



MARTA TORRENS
(Barcelona, Spain, EU)
**Depression and Anxiety in Dual
Disorder Opioid Addicts**



ICRO MAREMMANI
(Pisa, Italy, EU)
**Methadone Anticraving Dosages
and Opioid Debt in Opioid Use
Disorder Patients**

Organizing Committee
Ti.Gi. Congress, Via Udine, 12 - 58100 GROSSETO, Italy
Phone +39 0564412038 - Fax +39 0564412485
E-mail: giusi@tigicongress.com

AU-CNS, Via XX Settembre, 83 - 55045 PIETRASANTA, LU, Italy
Phone +39 0584790073
E-mail: info@aucns.org

FRIDAY JUNE 28, 2024

TIME	ABSTRACT NO	
○ PRE-CONFERENCE INVITED PRESENTATIONS		
14:00 15:30	ROOM A	PCIP01 - Preconference Invited Presentations Chair: Marc Reisinger (Brussels, Belgium, EU)
14:00 14:30	PCIP01-1	RADU IUGA (Geneva, Switzerland, CHE) - The Role of Diacetylmorphine in Reducing Crack Use and Promoting Retention in Treatment among Individuals with Co-Occurring Opioid and Crack Addiction.
14:30 15:00	PCIP01-2	RADU IUGA (Geneva, Switzerland, CHE) - The Geneva Crack Outreach Program.
15:00 15:30	PCIP1-3	AMIOTTE-SUCHET LOU (Grenoble, France, EU) - Between Knowledge and Representations: The Barriers in the Management of Opioid Use Disorder in French General Practitioners.
○ PRE-CONFERENCE LECTURES		
15:30 17:00	ROOM A	CONFERENCE Chair: <i>Mario Miccoli (Pisa, Italy, EU)</i>
15:30 16:00	PCL-1	CELIA FRANCO (Coimbra, Portugal, EU) - The Role of Mental Health Community Teams in Substances Use and Dual Disorders Patients
16:00 16:30	PCL-2	THOMAS CLAUSEN (Oslo, Norway) - The evolvement of a national OMT program in Norway with time; changing priorities
16:30 17:00	PCL-3	ADRIAN OCTAVIAN ABAGIU (Bucarest, Romania, EU) - Which Patients Are Doing Better in Methadone Maintenance Treatment? A Retrospective Study in Arena MMT Centre in Bucharest

FRIDAY JUNE 28, 2024

TIME	ABSTRACT NO	
<p>○ OPENING CEREMONY</p>		
	ROOM A	CONFERENCES <i>Chairs: Icro Maremmani (Pisa, Italy, EU)</i>
17:15 17:30	CF-0	LUIS PATRICIO (Lisbon, Portugal, EU) - Conference opening
17:30 18:00	CF-1	MARK PARRINO (New York, NY, USA) - Overdoses with opioid treatment/ long acting politics
18:00 19:00	CF-2	NICHOLAS LINTZERIS (Sydney, NSW, Australia) - Patient-Reported Outcomes of Treatment of Opioid Dependence with Weekly and Monthly Subcutaneous Depot
19:00 20:00	CF-3	MICHAEL KRAUSZ (Vancouver, BC, Canada) - Opioid Overdose Crisis in Northern America and Its Potential Impact on Europe
<p>○ WELCOME COCKTAIL AND CHIMERA AWARD 2024</p>		
20:00		THE ALESSANDRO TAGLIAMONTE AWARD <i>Chairs: Icro Maremmani (Pisa, Italy, EU), Marc Reisinger (Brussels, Belgium, EU) and Andrej Kastelic (Ljubljana, Slovenia, EU)</i>
		CHIMERA award 2024
		TO BE AWARDED: FRANCINA FONSECA (Barcelona, Spain, EU)
		CELIA FRANCO (Coimbra, Portugal, EU)
		ALBRECHT ULMER (Stuttgart, Germany, EU)
		CAREER AWARD: NICHOLAS LINTZERIS (Sydney, NSW, Australia)
		FRIEND OF THE FIELD AWARD: MARIO MICCOLI (Pisa, Italy, EU)
		 <p>CHIMERA AWARD European Opiate Addiction Treatment Association Award <i>"The Alessandro Tagliamonte Award"</i></p>   <p>"Dedicated to all those who dream of a better world for drug addicts"</p>
		 <p>PISA ROVAI SCHOLARS AWARD School of Addiction Medicine <i>"The Luca Rovai Award"</i></p>   <p>"Dedicated to all those who dream of a better world for drug addicts"</p>

Best poster Rovai Scholars award

Francina FONSECA, Miguel GARCÍA-JIMÉNEZ, Juan José FUENTES, Claudio CASTILLO, Maria De La Cabeza MARTÍNEZ, Irene CANOSA, Albert ROQUER, Sílvia MARTÍNEZ-LOPEZ, Alejandro ALCÁNTARA and Marta TORRENS (Barcelona, Spain, EU) - Characterization of Patients Addicted to Fentanyl Treated in an Addiction Community Center.

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD INVITED PRESENTATIONS		
8:00 9:30	ROOM A	IP01 - EUROPAD INVITED PRESENTATIONS <i>Chair: Angelo G. I. Maremmani (Pisa, Italy, EU)</i>
8:00 8:30	IP01-1	HEIKE ZURHOLD (Hamburg, Germany, EU) - OAT Attitudes in German Drug Scenes: Comparison of OAT Experienced with OAT Naive Opioid Dependent Persons
8:30 9:00	IP01-2	ALBRECHT ULMER (Stuttgart, Germany, EU) - Paradigm Shift (Opioid relevance) in the Treatment of Alcohol Addicts
9:00 9:30	IP01-3	OMRI SINAI (Jerusalem, Israel) - Case Series: Prospective Study: Efficacy of Pregabalin in Managing Opioid Withdrawal Syndrome with and without Dual Diagnosis Disorder
8:00 9:30	ROOM B	IP02 - EUROPAD INVITED PRESENTATIONS <i>Chair: Filippo Della Rocca (La Spezia, Italy, EU)</i>
8:00 8:30	IP02-1	SIMON OLIVIER (Lausanne, Switzerland) - Opioid Agonist Treatment in Switzerland: Quo Vadis?
8:30 9:00	IP02-2	DIPALI RINKER (Houston, TX, USA) - The Role of Race, Depression, HIV Symptomatology, and Pain Efficacy on Pain Anxiety among People Living with HIV in an Outpatient Infectious Disease Clinic
9:00 9:30	IP03-3	NUSA SEGREC (Ljubljana, Slovenia, EU) - The Role of Medication Assisted Treatment in Opioid Addiction and Functional Recovery of Patients
○ CONFERENCE		
	ROOM A	CONFERENCES <i>Chair: Yatan Pal Singh Balhara (New Delhi, India)</i>
9:30 10:00	CF-4	MARC REISINGER (Brussels, Belgium, EU) - Is It Possible to Detoxify Patients with a Long-Acting Opioid Medication?
10:00 10:30	CF-5	ANDREJ KASTELIC (Ljubljana, Slovenia, EU) - Experience with Buprenorphine S.C. Depot Injection and Induction with Microdosing in Slovenia

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
10:30 12:00	ROOM A	S01 - BUPRENORPHINE DEPOT EXPERIENCES <i>Chair: Nicholas Lintzeris (Sydney, NSW, Australia)</i>
10:30 11:00	S01-1	MARC AURIACOMBE (Bordeaux, France, EU) - A Prospective Observational Study in Naturalistic Settings to Describe Long-Acting Injectable Buprenorphine Introduction in France: The Obap Cohort Study
11:00 11:30	S01-2	ALICE DESCHENAU (Villejuif, France, EU) - Treatment of Opioid Dependence with Long-Acting Buprenorphine in Real Life in France: Retention on Treatment at 6 Months, Opale 2 Study
11:30 12:00	S01-3	CABÉ JULIEN (Clermont-Ferrand, France, EU) - Should the Prescription of Extended-Release Buprenorphine Be Reserved for a Specific Patient Profile? Answers from a Real-Life French Cohort
10:30 12:00	ROOM B	S02 - IMPACT OF COVID 19 PANDEMIC ON SUBSTANCE USE AND CONSEQUENCES: LESSONS LEARNED <i>Chair: Mercedes Lovrecic (Ljubljana, Slovenia, EU)</i>
10:30 11:00	S02-1	MATEJA ROK SIMON (Ljubljana, Slovenia, EU) - Hospital Admissions for Alcohol, Cannabinoids, Benzodiazepines and Narcotics-Related Intoxications among Children, Adolescents and Young Adults in Slovenia in the Period before and after the Start of the Covid-19 Pandemic
11:00 11:30	S02-2	BARBARA LOVRECIC (Ljubljana, Slovenia, EU) - Retrospective Cohort Study on Heroin Addicts in Opioid Agonist Treatment Programme in the 22 Years Period: Causes of Death before and after Covid 19 Pandemic Start
11:30 12:00	S02-3	MERCEDES LOVRECIC (Ljubljana, Slovenia, EU) - Mild Cognitive Impairment and Dementia among Heroin Addicts in Outpatient Opioid Agonist Treatment
○ CONFERENCES		
	ROOM A	CONFERENCES <i>Chair: Jean Pierre Daulouede (Bayonne, France, EU)</i>
12:00 13:00	CF-6	MAURICE DEMATTEIS (Grenoble, France, EU) - Treating pain in OUD patients
13:00 14:00	CF-7	ANGELO G. I. MAREMMANI (Pisa, Italy, EU) - Chronic Psychoses and Opioid Medications
LUNCH		
○ EUROPAD SYMPOSIA		
15:00 16:30	ROOM A	S03 - OPIOID AGONIST TREATMENT (OAT) IN EUROPEAN PRISONS: TREATMENT NEEDS, ALTERNATIVE APPROACHES AND IMPLEMENTATION <i>Chairs: Fadi Meroueh (Montpellier, France, EU) Filipa Alves da Costa (WHO Regional Office for Europe)</i>
15:00 15:20	S03-1	HEINO STOVER (Frankfurt, Germany, EU) - OAT in Prison: An Introductory Reflection on the Needs, Benefits and Approaches to OAT in Prison
15:20 16:40	S03-2	LINDA MONTANARI (Lisbon, Portugal, EU) - What Is the Evidence-Base Driving Policy Decisions in Europe? Overview of Latest Available Data on OAT Provision, Coverage and Approaches in European Countries. Data Gaps
16:40 16:00	S03-3	ANJA BUSSE (Vienna, Austria, UNODC) - International Standards and Guidance for the Management of Opioid Use Disorders in Prison
16:00 16:10	S03-4.1	FILIPA ALVES DA COSTA - Case Studies: The Portuguese Approach to OAT in Prison (Focus on Methadone)
16:10 16:20	S03-4.2	FADI MEROUEH (Montpellier, France, EU) - Case Studies: The French Approach to OAT in Prison (Focus on Long-Acting Buprenorphine)
16:20 16:40	S03-4.3	NIJOLE GOSTAUTAITE (Montpellier, France, EU) - Case Studies: The Lithuanian Approach to OAT in Prison (Focus on Combined Buprenorphine/Naloxone)

SATURDAY JUNE 29, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
15:00 16:30	ROOM B	S04 - INVITED ORAL PRESENTATIONS <i>Chair: Alexander Kantchelov (Sofia, Bulgaria, EU)</i>
15:00 15:30	S04-1	VINCENZA SPERA (Mendrisio, Switzerland) - A-ADHD: Patterns of Use, Related Clinical Features and Different Impact of Cannabis, Cocaine, Alcohol, and Heroin Use
15:30 16:00	S04-2	MANUEL GLAUCO CARBONE (Varese, Italy, EU) - Opioid Use Disorder and Migration
16:00 16:30	S04-3	MATTEO PACINI (Pisa, Italy, EU) - Opioid Use Disorder and Polysubstance Use
○ CONFERENCES		
	ROOM A	CONFERENCES <i>Chair: Maurice Dematteis (Grenoble, France, EU)</i>
16:30 17:00	CF-8	MARTA TORRENS (Barcelona, Spain, EU) - Depression and Anxiety in Dual Disorders Heroin Addicts
17:00 17:30	CF-9	MARC AURIACOMBE (Bordeaux, France, EU) - Why Is Craving So Important? What to Do About It?
○ EUROPAD SYMPOSIA		
17:30 19:00	ROOM A	S05 - PSYCHOTHERAPY IN OPIOID ADDICTION TREATMENT <i>Chair: Alexander Kantchelov (Sofia, Bulgaria, EU)</i>
17:30 18:00	S05-1	TSVETANA STOYKOVA (Sofia, Bulgaria, EU) - The Therapeutic Continuum in the Context of Methadone-Assisted Psychotherapy
18:00 18:30	S05-2	ALEXANDER BELCHEV (Luton, Bedfordshire, UK) - Optimal Strategies for Ballancing Treatment Targets with Clients' Goals in the Context of Disruptive Affect
18:30 19:00	S05-3	RIK BES (Alkmaar, Netherlands, EU) - The Forest and the Trees: In Search of Effective Psychotherapists
17:30 19:00	ROOM B	S06 - ASSESSING HEROIN USE DISORDER <i>Chair: Mario Miccoli (Pisa, Italy, EU)</i>
17:30 18:00	S06-1	MANUEL GLAUCO CARBONE (Varese, Italy, EU) - The Psychopathology Specific to SUD
18:00 18:30	S06-2	ANGELO G. I. MAREMMANI (Pisa, Italy, EU) - An Inventory for Assessing the Behavioural Covariates of Craving in Heroin Use Disorder Patients
18:30 19:00	S06-3	FILIPPO DELLA ROCCA (Pisa, Italia, EU) - The Tals – Reduced Form: An Inventory for Assessing the Heroin Post-Traumatic Stress Disorder Spectrum (H/PTSD-S)
20:00		SOCIAL DINNER*
		* Tickets are available for all delegates

SUNDAY JUNE 30, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
8:30 10:00	ROOM A	IP03 - EUROPAD INVITED PRESENTATIONS <i>Chair: Filippo Della Rocca (La Spezia, Italy, EU)</i>
8:30 9:00	IP03-1	BRIDIN MURNION (Sydney, Australia, AUS) - Barriers and Facilitators to Physical Health Care Experienced by People with Opioid Dependence
9:00 9:30	IP03-2	CÉU MATEUS (Lancaster, UK) - Experiences of and Outcomes for Blackpool Adults Who Are Treated with Buprenorphine Prolonged-Release Injection (Buvidal) Opioid Substitution Therapy
9:30 10:00	IP03-3	FELIPE LOZANO-ROJAS (Athens, GA, USA) - The Effect of Medical Cannabis Laws on Use of Pain Medications among Commercially Insured Patients in the United States
8:30 10:00	ROOM B	IP04 - EUROPAD INVITED PRESENTATIONS <i>Chair: Manuel Glauco Carbone (Varese, Italy, EU)</i>
8:30 9:00	IP04-1	LILJANA IGNJATOVA (Skopje, North Macedonia) - Predictors of Outcome in Methadone Maintenance Treatment
9:00 9:30	IP04-2	LINDA HURLEY (Cranston, RI, USA) - Providing Methadone and Buprenorphine from a Mobile Unit
9:30 10:00	IP04-3	SOFIA GOLBREICH (Bat Yam, Israel) - Case Series: Prospective Study: Efficacy of Pregabalin in Managing Opioid Withdrawal Syndrome with and without Dual Diagnosis Disorder
○ CONFERENCES		
	ROOM A	CONFERENCE 6 <i>Chair: Luis Patricio (Lisbon, Portugal, EU)</i>
10:00- 10:30	CF-10	GABRIELE FISCHER (Vienna, Austria, EU) - Medical Standards and Human Rights for Diagnosis and Treatment of Opioid Dependence in Prison
10:30 11:00	CF-11	LORENZO SOMAINI (Biella, Italy, EU) - What Is Changing with Opioid Long-Acting Medications?

SUNDAY JUNE 30, 2024

TIME	ABSTRACT NO	
○ EUROPAD SYMPOSIA		
11:00 12:30	ROOM A	IP05 - EUROPAD INVITED PRESENTATIONS <i>Chair: Lorenzo Somaini (Biella, Italy, EU)</i>
11:00 11:30	IP05-1	FRANCINA FONSECA (Barcelona, Spain, EU) - Value Stream Mapping Methodology for Improving Access to Hepatitis C Treatment in Opioid Addiction
11:30 12:00	IP05-2	DESIREE EIDE (Oslo, Norway) - Norway's First Heroin-Assisted Treatment Clinics: Initial Impact of the Intervention
12:00 12:30	IP05-3	FILIPPO DELLA ROCCA (La Spezia, Italy, EU) - Exploring the Depressive Syndrome of Heroin Use Disorder Patients. Relationships between Worthlessness/Being Trapped, Deficit Reward and Post-Withdrawal Syndromes
11:00 12:30	ROOM B	IP06 - EUROPAD INVITED PRESENTATIONS <i>Chair: Celia Franco (Coimbra, Portugal, EU)</i>
11:00 11:30	IP06-1	RAMINTA DANIULAITYTE (Phoenix, AZ, USA) - "Fentanyl Made Heroin Not Work Anymore": Exploring Transitions from Heroin to Illicitly Manufactured Fentanyl Use in Arizona, USA
11:30 12:00	IP06-2	JONATHAN DALE CHICK (North Berwick, Scotland, UK) - Prescribing Psychiatric Medications in Alcohol Use Disorders and Other Addictions: Risks and Avoiding Risk
12:00 12:30	IP06-3	DAVID BRADFORD (Athens, GA, USA) - The Effect of a Large Prescription Opioid Diversion Event on Opioid Mortality in the U.S.
○ CONFERENCE		
12:30 13:30	ROOM A	CONFERENCE 7 <i>Chair: Marta Torrens (Barcelona, Spain, EU)</i>
12:30 13:00	CF-12	ICRO MAREMMANI (Pisa, Italy, EU) - Methadone anticraving dosages and opioid debt in OUD patients
13:00 13:30	CF-13	EINAT PELES (Tel Aviv, Israel) - Nutrition, Eating Habits and Weight Reduction Intervention among Opioid Maintenance Treatment Patients
13:30 13:45	CLOSING REMARKS	ICRO MAREMMANI (Pisa, Italy, EU) - Closing remark and see you in Bucarest (Romania) in May 2026

POSTERSESSION

P01	Amanda J. ABRAHAM and Felipe LOZANO-ROJAS (Athens, GA, USA) - Introduction of Medicare Coverage of Services Delivered in Opioid Treatment Programs in the United States
P02	Roberto CICCOCIOPPPO, Luisa DE VIVO, Laura SOVERCHIA, Massimo UBALDI, Veronica LUNERTI and Nazzareno CANNELLA (Camerino, Italy, EU) - Long-Access Heroin Self-Administration Induces Region Specific Reduction of Grey Matter Volume and Microglia Reactivity in Nih Heterogeneous Stock Rats
P03	Sara DE CARLO, Hela MRIZAK, Andrea DELLA VALLE, Veronica LUNERTI, Alessandra MAMMONE, Manthoula KYRATZI, Antonio LACORTE, Adana KESHISHIAN, Min LI, Esi DOMI, Massimo UBALDI, Roberto CICCOCIOPPPO and Nazzareno CANNELLA (Camerino, Italy, EU) - Predicting Individual Treatment Response in Alcohol Use Disorder: A Reverse Translational Proof-of-Concept Study
P04	Simone DE PERSIS, Marta MATRONE, Andrea ROMANO, Giulia MOLTONI and Paola MOTTA (Rieti, Italy, EU) - Alterations in Resting-State Functional Connectivity of the Salience Network in Patients with Schizophrenia with and without Cannabis Use Disorder Comorbidity
P05	Miguel DIAZ and Charlotta TEGNESTEDT (Huddinge, Sweden, EU) - The Spectrum of Addiction: Biological, Behavioral, and Therapeutic Dimensions
P06	Silvia DIAZ-FERNANDEZ and Juan J. FERNANDEZ-MIRANDA (Gijón, Spain, EU) - Sociodemographic, Clinical and Treatment Differences by Gender in Addictive and Psychiatric Disorders Comorbidity
P07	Juan J. FERNANDEZ-MIRANDA and Silvia DIAZ-FERNANDEZ (Gijón, Spain, EU) - Dual Diagnoses in Mental Health or Addiction Treatment Settings in Spain: Clinical Differences
P08	Francina FONSECA, Miguel GARCÍA-JIMÉNEZ, Juan José FUENTES, Claudio CASTILLO, Maria De La Cabeza MARTÍNEZ, Irene CANOSA, Albert ROQUER, Sílvia MARTÍNEZ-LOPEZ, Alejandro ALCÁNTARA and Marta TORRENS (Barcelona, Spain, EU) - Characterization of Patients Addicted to Fentanyl Treated in an Addiction Community Center
P09	Katherine HATCHER, Vahe HEBOYAN and Gianluca DE LEO (Augusta, GA, USA) - Factors and Barriers Associated with Oud Treatment Seeking Behavior among Adults in the United States: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions – Iii
P10	Vahe HEBOYAN, Katherine HATCHER and Gianluca DE LEO (Augusta, GA, USA) - Prevalence and Correlates of Opioid Use in the United States: Findings from the National Epidemiologic Survey on Alcohol and Related Conditions – III
P11	Ali KHERADMAND, Helya HELALI, Faraj TABEIE and Shiva ILIAIEE (Tehran, Iran) - The Effect of Photobiomodulation on Reducing Anxiety, Depression, and Opioid Craving in Patients with Methadone Maintenance Treatment
P12	Alexander V. KHODZHAEV, Julia KAMINSKAYA, M., Sergey I. OSIPCHIK, Inessa V. GRIGORIEVA and Sergey A. IGUMNOV (Minsk, Belarus) - Organisation of an Opioid Substitute Therapy Program in the Republic of Belarus
P13	Beata KREMBUSZEWSKI, Emma ANDERSON-WHITE and Craig HENDERSON (Millbury, TX, USA) - Positive Psychology as a Protective Factor for Illicit Opioid Use in Individuals Receiving Methadone Treatment
P14	Hongwu LI, Veronica LUNERTI, Qianwei SHEN, Federica BENVENUTI, Laura SOVERCHIA, Nazzareno CANNELLA and Roberto CICCOCIOPPPO (Camerino, Italy, EU) - Cebranopadol, a Novel Long-Acting Opioid Agonist with Low Abuse Liability, to Treat Opioid Use Disorder: Preclinical Evidence of Efficacy
P15	Jan LIGON (Atlanta, GA, USA) - Usefulness of a Brief Educational Event to Challenge Provider Approaches with Families Affected by Substance Abuse
P16	Michelle LOFWALL, Edward NUNES, Sharon WALSH, Genie BAILEY, Michael FROST, Natalie BUDILOVSKY-KELLEY, Elin BANKE NORDBECK and Fredrik TIBERG (Lexington, KY, USA) - Dosing to Effect with Subcutaneous and Sublingual Buprenorphine for Opioid Use Disorder
P17	Rosemarie MARTIN, Jennifer WOOD, Alyssa DACUNHA, Amelia BAILEY, Lauren PERRON, Steven BELENKO, Lynda STEIN and Damaris ROHSENOW (Providence, RI, USA) - Identifying Gaps in Connecting People on Probation to Community-Based Substance Use Services Using Action Planning and Goals among Justice-Provider Partnerships
P18	Rosemarie MARTIN, Ryan CARPENTER, Ariel HOADLEY, Amelia BAILEY, Alyssa DACUNHA, Augustine KANG, Josiah RICH, Damaris ROHSENOW, Linda HURLEY and Jennifer CLARKE (Providence, RI, USA) - Providing Evidence-Based Addiction Treatment During Incarceration Decreases Overdose Deaths after Incarceration
P19	Kaisa MISHINA, Jasmin LOSTEDT and Solja NIEMELÄ (Turku, Finland, EU) - Perceived Discrimination among People Who Inject Opioids

P20	Stefan PETERSON, Edward NUNES, Michelle LOFWALL, Sharon WALSH and Fredrik TIBERG (Lund, Sweden, EU) - Exploring Opioid Use Disorder Outcomes by Quantitative Urine Analysis: Post-Hoc Analysis of a Phase 3 Randomised Clinical Trial Comparing a Subcutaneous Buprenorphine Depot (Cam2038) and Sublingual Buprenorphine
P21	Di QIN, Nazzareno CANNELLA, Laura SOVERCHIA, Massimo UBALDI and Roberto CICCOCIOPPO (Camerino, Italy, EU) - Nih Heterogeneous Stock Rats Trained to Heroin Self-Administration Show Heterogeneous Response to the Anti-Addictive Effects of the Mop/Nop Agonist Cebranopadol
P22	Anat SASON and Einat PELES (Tel-Aviv, Israel) - Patients' Anxiety Levels and Their Reactions Towards the Needed Changes of Policies in Methadone Maintenance Treatment Following the October 7th Events
P23	Aneta SPASOVSKA TRAJUANOVSKA (Skopje, North Macedonia) - The Effectiveness of Escitalopram Use in the Treatment of Anxiety Conditions in Patients on Metadone Treatment
P24	Massimo UBALDI, Hela MRIZAK, Veronica LUNERTI, Laura RULLO, Esi DOMI, Patrizia ROMUALDI, Roberto CICCOCIOPPO and Nazzareno CANNELLA (Camerino, Italy, EU) - Increased Mop Expression in the Ventral Tegmental Area Mediates Higher Heroin Self-Administration and Motivation Expressed by Marchigian Sardinian Alcohol Preferring Rats Compared to Non-Preferring Wistars



PISA **ROVAI SCHOLARS AWARD**
School of Addiction Medicine
"The Luca Rovai Award"
"Dedicated to all those who dream of a better world for drug addicts"

Rovai Scholars award, named after one of the founding member of PISA-School of Addiction Medicine Dr. Luca Rovai is a prestigious title in the field of Psychiatry and Addiction Medicine granted by the PISA-School of Addiction Medicine and the Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS) to a select group of promising residents in Psychiatry and Addiction Medicine and young specialists in these fields.

FORMER RECIPIENTS:

From Intense to Occasional Use of Cocaine in Dual Disorder (ADHD/Cocaine Use Disorder) Patients Treated with Stimulant Medications by C. Manni, A. Pallucchini, G. Cipollone, V. Spera, M. Maiello, M. Novi, G. Perugi and I. Marenmani (Pisa, Italy, EU). Poster presented at *New paradigms for mental disorders: Neurodevelopmental, neuroprogressive and neurodegenerative perspectives* Pisa, Italy, October 22-23 2018

High Risk Drinking and Prescription Drug Misuse: Relationship with Suicidal Ideation among US National Guard Soldiers by F. C. Blow, R. V. Ignacio, R. McCormick, M. A. Walton, A. S. B. Bohnert, M. A. Ilgen (Ann Arbor, MI, USA). Poster presented at *2° World Congress of the World Association on Dual Disorders (WADD)*, Florence, October 25-27 2018

Naturalistic Follow-up in Bipolar Patients after Successful Electroconvulsive Therapy by M. Novi, M. Barbuti, B. Tripodi, A. Boccolini, G. Gemmellaro, F. De Dominicis, C. Elefante, L. Lattanzi, P. Medda, and G. Perugi (Pisa, Italy, EU). Poster presented at *Neurodevelopmental Psychopathology in Adults: Depressive, Bipolar, Psychotic and Substance Use Disorders*, Pisa, Italy, EU, July, 8-9 2019

High therapeutic buprenorphine levels reduce i.v. fentanyl respiratory depression by M. G. Tocco, K. Wiest, M. H. Algera, L. Moss, M. van Velzen, G. J. Groeneveld, J. Heuberger, A. Dahan, F. Gray, S. Strafford, R. Dobbins (Milan, Italy, EU). Poster presented at *14th EUROPAD European Congress*, Grenoble, France, November 19-21, 2021

Early experience of buprenorphine long-acting injection in Finland. A retrospective cohort study by M. Partanen, T. Saarenpää, T. Prami, I. Iso-Mustajärvi, B. Ryder and K. Simojoki (Turku, Suomi, Finland, EU). Poster presented at *15th European Congress of EUROPAD*, Pisa, Italy, May 20-22, 2022

Alexithymia as a Risk Factor of Addictive Behavior by Sergey Igumnov and Lapanov Pavel (Minsk, Belarus - Gomel, Belarus). Poster presented at *WADD 7th World Congress*, Portoroz, Slovenia, April 28-30, 2023

FACULTY	
ADRIAN OCTAVIAN ABAGIU	Center for Integrated Services for Addiction National Institute for Infectious Diseases, Bucarest, Romania
AMANDA ABRAHAM	University of Georgia, Athens, GA, USA.
FILIPA ALVES DA COSTA	WHO Regional Office for Europe, Lisbon, Portugal
MARC AURIACOMBE	Head of Addiction Research and Clinical Services, Addiction Psychiatry, Victor Segalen University, Bordeaux, France, EU.
YATAN PAL SINGH BALHARA	Lady Hardinge Medical College and SSK Hospital, New Delhi, India
ALEXANDER BELCHEV	Luton, Bedfordshire, Luton, Bedfordshire, UK.
RIK BES	Centre for Motivation and Change (CMC), Alkmaar, Netherlands, EU.
DAVID BRADFORD	University of Georgia, GA, USA.
ANJA BUSSE	United Nations Office on Drugs and Crime, Vienna, Austria.
MANUEL GLAUCO CARBONE	Department of Psychiatry, University Hospital, Varese, Italy, EU.
JONATHAN DALE CHICK	Consultant Psychiatrist, Castle Craig Hospital, North Berwick, Scotland, UK.
ROBERTO CICCOCIOPPO	University of Camerino, Camerino, Italy, EU.
THOMAS CLAUSEN	Norwegian Centre of Addiction Research, University of Oslo, Oslo, Norway
RAMINTA DANIULAITYTE	ASU College of Health Solutions, Phoenix, AZ, USA.
JEAN PIERRE DAULOUEDE	Bizia, Bayonne, France, EU
SARA DE CARLO	UNICAM, Camerino, Italy, EU.
SIMONE DE PERSIS	ASL Rieti and University of Rome "La Sapienza", Italy, EU.
FILIPPO DELLA ROCCA	Addiction Unit, Department of Mental Health and Addictions, ASL5 Liguria NHS, La Spezia, Italy, EU - School of Addiction Medicine, Pisa, Italy.
MAURICE DEMATTEIS	University of Grenoble, France, EU.
ALICE DESCHENAU	General Hospital Paul Guiraud, Villejuif, France, EU.
MIGUEL DIAZ	Swedish Red Cross University, Huddinge, Sweden, EU.
SILVIA DIAZ-FERNANDEZ	Asturian Mental Health Service, Gijón, Spain, EU.
DESIREE EIDE	Norwegian Centre for Addiction Research, Oslo, Norway.
JUAN J. FERNANDEZ-MIRANDA	Asturian Mental Health Service, Gijón, Spain, EU.
GABRIELE FISCHER	Addiction Clinic, Medical University of Vienna, Center for Public Health & Department of Psychiatry and Psychotherapy, Vienna, Austria, EU.
FRANCINA FONSECA	Mental Health Institute - Hospital del Mar Research Institute, Barcelona, Spain, EU.
CELIA FRANCO	Coordinator of the Addiction Service of HSC, Coimbra, Portugal, EU
SOFIA GOLBREICH	Abarbanel Mental Health Centre, Bat Yam, Israel.
NIJOLE GOSTAUTAITE	Lithuanian Prison Services, Vilnius, Lithuania.
KATHERINE HATCHER	Augusta University, GA, USA.
VAHE HEBOYAN	Augusta University, GA, USA.
LINDA HURLEY	CODAC Behavioral Healthcare, Cranston, RI, USA.
LILJANA IGNJATOVA	University of Skopje, Macedonia, MKD.
RADU IUGA	University Hospital Geneva, Geneva, Switzerland

CABÉ JULIEN	University Hospital of Clermont Ferrand, Clermont Auvergne University, Clermont-Ferrand, France, EU.
ALEXANDER KANTCHELOV	Kantchelov Clinic, Sofia, Bulgaria, EU
ANDREJ KASTELIC	Center for Treatment of Drug Addiction, University Psychiatric Clinic, Ljubljana, Slovenia, EU.
ALI KHERADMAND	Department of Psychiatry, Taleghani Hospital Research Development Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
ALEXANDER V. KHODZHAEV	Republican Scientific and Practical Center for Mental Health, Minsk, Belarus.
MICHAEL KRAUSZ	UBC Providence Leadership Chair for Addiction Research, Professor of Psychiatry and School of Population and Public Health, Medical Director Burnaby Treatment Centre for Mental Health and Addiction, St Paul's Hospital, University of British Columbia, Vancouver, BC, Canada.
BEATA KREMBUSZEWSKI	Sam Houston State University, Millbury, TX, USA.
HONGWU LI	Changchun University of Technology, China and University of Camerino, Italy, EU.
AMIOTTE-SUCHET LOU	Grenoble Alpes University Hospital, Grenoble, France, EU
JAN LIGON	Georgia State University, Atlanta, GA, USA.
NICHOLAS LINTZERIS	Specialty of Addiction Medicine, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
MICHELLE LOFWALL	University of Kentucky College of Medicine, Center on Drug and Alcohol Research, Lexington, KY, USA.
BARBARA LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU.
MERCEDES LOVRECIC	National Institute of Public Health, Ljubljana, Slovenia, EU.
FELIPE LOZANO-ROJAS	University of Georgia, Athens, GA, USA.
ANGELO G. I. MAREMMANI	Institute of Behavioural Sciences, Pisa, Italy, EU - PISA-School of Addiction Medicine, Pisa, Italy, EU.
ICRO MAREMMANI	Institute of Behavioural Sciences, Pisa, Italy, EU - PISA-School of Addiction Medicine - UNICAMILLUS, Rome, Italy, EU.
ROSEMARIE MARTIN	Brown University School of Public Health, Providence, RI, USA.
ROK SIMON MATEJA	National Institute of Public Health, Ljubljana, Slovenia, EU.
CÉU MATEUS	Lancaster University, Lancaster, United Kingdom.
FADI MEROUEH	Prison of Villeneuve les Maguelone, Montpellier, France, EU.
MARIO MICCOLI	Department of Clinical and Experimental Medicine, University of Pisa, Italy, EU
KAISA MISHINA	University of Turku, Turku, Finland, EU.
LINDA MONTANARI	European Monitoring Centre for Drugs and Drug Addiction, Lisbon, Portugal, EU.
BRIDIN MURNION	St Vincents Clinical School, University of New South Wales, Sydney, Australia, AUS.
SIMON OLIVIER	Addiction Medicine, Lausanne University Hospital, Lausanne, Switzerland.
MATTEO PACINI	Institute of Behavioural Sciences, Pisa, Italy, EU - PISA-School of Addiction Medicine, Pisa, Italy, EU.

MARK PARRINO	American Association for the Treatment of Opioid Dependence, New York, NY, USA.
EINAT PELES	Dr. Miriam & Sheldon G. Adelson Clinic for Drug Abuse, Treatment & Research, Adelson Clinic for Drug Abuse Treatment & Research, Tel Aviv Sourasky Medical Center, Tel Aviv University.
LOUIS PATRICIO	EUROPAD Portugal, Lisbon, Portugal, EU
STEFAN PETERSON	Camurus AB, Lund, Sweden, EU.
DI QIN	School of Pharmacy, Pharmacology Unit University of Camerino, Camerino, Italy, EU.
MARC REISINGER	European Association for the Treatment of Opiate Addiction, Brussels, Belgium, EU - World Federation for the Treatment of Opioid Dependence, New York, NY, USA.
DIPALI RINKER	University of Houston, Houston, TX, USA.
ANAT SASON	Adelson Clinic for Drug Abuse Treatment & Research, Tel-Aviv, Israel.
NUSA SEGREC	Centre for Treatment of Drug Addiction, Ljubljana University Psychiatric Hospital, Ljubljana, Slovenia, EU.
OMRI SINAI	Abarbanel Mental Health Center, Jerusalem, Israel.
LORENZO SOMAINI	Department of Addiction Medicine, Biella, Italy, EU.
ANETA SPASOVSKA TRAJANOVSKA	University of Skopje, North Macedonia.
HEINO STOVER	University of Applied Sciences, Faculty of Health and Social Work, Frankfurt, Germany, EU.
VINCENZA SPERA	Psychiatric Hospital, Sociopsychiatric Organization, Mendrisio, Switzerland.
TSVETANA STOYKOVA	The Kantchelov Clinic, Sofia, Bulgaria, EU.
MARTA TORRENS	Addiction Unit, Institute of Psychiatry and Addictions, Hospital del Mar-IMIM, University of Barcelona, Spain, EU.
MASSIMO UBALDI	University of Camerino, Camerino, Italy, EU.
ALBRECHT ULMER	Institute for Addiction Research, Stuttgart, Germany, EU.
HEIKE ZURHOLD	Senior Researcher, University of Hamburg, Germany, EU.



CHIMERA AWARD

European Opiate Addiction Treatment Association Award

"The Alessandro Tagliamonte Award"



"Dedicated to all those who dream of a better world for drug addicts"

FORMER RECIPIENTS:

Adrian-Octavian Abagiu (Romania) - Pisa, Italy, 2022
Hannu Alho (Finland) - Pisa, Italy, 2022
Marc Auriacombe (France) - Oslo, Norway, 2002
Olof Blix (Sweden) - Arezzo, Italy, 2000
Miguel Casas (Spain) - Barcelona, Spain, 2012
Thomas Clausen (Norway) - Glasgow, Scotland, UK, 2014
Pascal Courty (France) - Barcelona, Spain, 2012
Jean-Jacques Deglon (Switzerland) - Paris, France, 2004
Maurice Dematteis (France) - Krakow, Poland, 2018
Sergey Dvoryak (Ukraine) - Zagreb, Croatia, 2010
Gabriele Fischer (Austria) - Sofia, Bulgaria, 2008
Gilberto Gerra (Italy) - Bratislava, Slovakia, 2006
Liljana Ignjatova (North Macedonia) - Pisa, Italy, 2022
Ante Ivancic (Croatia) - Bratislava, Slovakia, 2006
Alexander Kantchelov (Bulgaria) - Paris, France, 2004
Andrej Kastelic (Slovenia) - Sofia, Bulgaria, 2008
Mercedes Lovrecic (Slovenia) - Oslo, Norway, 2002
Angelo G. I. Maremmani (Italy) - Grenoble, France, 2021
Vladimir Mendelevich (Russia) - Glasgow, Scotland, UK, 2014
Genci Mucollari (Albania) - Grenoble, France, 2021
Lubomir Okruhlica (Slovakia) - Oslo, Norway, 2002
Matteo Pacini (Italy) - Krakow, Poland, 2018
Pier Paolo Pani (Italy) - Paris, France, 2004
Luis Patricio (Portugal) - Zagreb, Croatia, 2010
Einat Peles (Israel) - Leiden, Netherlands, 2016
Slavko Sakoman (Croatia) - Zagreb, Croatia, 2010
Lorenzo Somaini (Italy) - Glasgow, Scotland, UK, 2014
Marta Torrens (Spain) - Bratislava, Slovakia, 2006
Didier Touzeau (France) - Sofia, Bulgaria, 2008
Ambros Uchtenhagen (Switzerland) - Leiden, Netherlands, 2016
Peter Vossenberg (The Netherlands) - Leiden, Netherlands, 2016
Helge Waal (Norway) - Barcelona, Spain, 2012
Stephan Walcher (Germany) - Grenoble, France, 2021
Gabrielle Welle-Strand (Norway) - Krakow, Poland, 2018

FORMER CAREER AWARD RECIPIENTS:

Jean-Pierre Daulouede (France) - Leiden, Netherlands, 2016
Loretta Finnegan (USA) - Zagreb, Croatia, 2010
Mary Jeanne Kreek (USA) - Glasgow, Scotland, UK, 2014
Herman Joseph (to memory - USA) - Grenoble, France, 2021
Joyce Lowinson (USA) - Pietrasanta, Italy, 2007
Icro Maremmani (Italy) - Paris, France, 2004
Robert Newman (USA) - Barcelona, Spain, 2012
Marc Reisinger (Belgium) - Paris, France, 2004
Mark Parrino (USA) - Krakow, Poland, 2018
Sir John Strang (UK) - Pisa, Italy, 2022
Alessandro Tagliamonte (Italy) - Paris, France, 2004



camurus®



MOLTENI®
FARMACEUTICI 1892 | 2017

125